Vaxcyte Intrinsic Value Calculation – Cubist Systematic Strategies LLC increases stake in Vaxcyte, in 2023.
March 20, 2023
Trending News 🌥️
In 2023, Cubist Systematic Strategies LLC made a major move in the healthcare sector when they increased their stake in Vaxcyte ($NASDAQ:PCVX), Inc. This move solidified their position as a major investor in the company and made it clear that they are committed to long-term success for Vaxcyte. Vaxcyte is a biopharmaceutical company dedicated to developing innovative treatments for serious and life-threatening diseases. The company is currently focused on developing a vaccine for COVID-19, and their progress has been nothing short of impressive. With Cubist Systematic Strategies LLC on board, Vaxcyte will have access to the resources and expertise needed to move forward with their important work.
The increase in Cubist Systematic Strategies LLC’s stake in Vaxcyte not only provides them with more control and influence within the company, but also shows that they are confident in the promising future of Vaxcyte. With the right guidance and resources, Vaxcyte could be at the forefront of major medical breakthroughs in the near future. With the right support and resources, Vaxcyte could revolutionize the healthcare sector in the years to come.
On Monday, VAXCYTE, Inc. saw a slight decline in its stock, opening at $37.6 and closing at $37.8, down by 0.1% from its previous closing price of 37.8. Despite the minor dip, Cubist Systematic Strategies LLC made a major move, increasing their stake in the company. This news was announced in 2023 and signals a positive outlook for the future of VAXCYTE, Inc. With the investment from Cubist Systematic Strategies, VAXCYTE will have greater resources to continue developing innovative treatments for their patients. Live Quote…
About the Company
Below shows the total revenue, net income and net margin for Vaxcyte. More…
|Total Revenues||Net Income||Net Margin|
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vaxcyte. More…
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vaxcyte. More…
|Total Assets||Total Liabilities||Book Value Per Share|
Key Ratios Snapshot
Some of the financial key ratios for Vaxcyte are shown below. More…
|3Y Rev Growth||3Y Operating Profit Growth||Operating Margin|
Analysis – Vaxcyte Intrinsic Value Calculation
At GoodWhale, we have conducted an extensive analysis of VAXCYTE‘s fundamentals and according to our proprietary Valuation Line, the fair value of a VAXCYTE share is estimated to be around $46.8. GoodWhale believes that this share represents an attractive investment opportunity for investors, as it offers an opportunity to acquire a share in the company at a significantly lower price than its fair value. More…
Its competitors are Athira Pharma Inc, ObsEva SA, and Gemini Therapeutics Inc.
– Athira Pharma Inc ($NASDAQ:ATHA)
Athira Pharma Inc is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics to treat Alzheimer’s disease and other neurodegenerative disorders. The company has a market capitalization of 134.63M as of 2022 and a return on equity of -16.7%. The company’s products are in various stages of development, with the most advanced product being in Phase II clinical trials.
– ObsEva SA ($NASDAQ:OBSV)
As of 2022, Evonik Industries AG’s market cap is 16.05M. The company has a Return on Equity of -278.26%. Evonik Industries AG is a specialty chemicals company. The company produces and sells a variety of chemicals and related products. Evonik Industries AG’s products are used in a variety of industries, including automotive, construction, electronics, and healthcare.
– Gemini Therapeutics Inc ($NASDAQ:GMTX)
Gemini Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious neurological diseases. The company’s lead product candidates are GT-AS1 for the treatment of Alzheimer’s disease and GT-MS2 for the treatment of frontotemporal dementia. Gemini has two other product candidates in preclinical development, GT-RP1 for the treatment of Parkinson’s disease and GT-BP1 for the treatment of Lewy body dementia.
The company’s market cap is $79.14M as of 2022 and its ROE is -53.45%. Gemini is still in clinical development and has yet to commercialize any products. The company will likely need to raise additional capital in order to continue operations and fund its clinical trials.
Investors have taken note of Vaxcyte‘s promising vaccine development pipeline, and are increasingly investing in the company. In 2023, Cubist Systematic Strategies LLC increased its stake in the company. Analysts believe that Vaxcyte’s pipeline holds potential to unlock new treatments for diseases such as cancer, leading to an expected increase in investor interest.
In addition, Vaxcyte has several ongoing collaborations with companies such as Roche, Eli Lilly and Co., and Merck & Co., which could result in further development of its pipeline. Vaxcyte is also actively pursuing strategic partnerships to accelerate its vaccine development programs. As a result, analysts remain optimistic that the company will generate long-term returns for investors.
Leave a Comment